An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation

Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilinski, Pretoria, Webb, Myles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596197/
https://www.ncbi.nlm.nih.gov/pubmed/33145175
http://dx.doi.org/10.1016/j.eucr.2020.101467
_version_ 1783602052462542848
author Bilinski, Pretoria
Webb, Myles
author_facet Bilinski, Pretoria
Webb, Myles
author_sort Bilinski, Pretoria
collection PubMed
description Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment. This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.
format Online
Article
Text
id pubmed-7596197
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75961972020-11-02 An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation Bilinski, Pretoria Webb, Myles Urol Case Rep Oncology Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment. This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver. Elsevier 2020-10-24 /pmc/articles/PMC7596197/ /pubmed/33145175 http://dx.doi.org/10.1016/j.eucr.2020.101467 Text en © 2020 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Bilinski, Pretoria
Webb, Myles
An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title_full An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title_fullStr An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title_full_unstemmed An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title_short An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
title_sort exceptional response to (177)lupsma undermined by neuroendocrine transformation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596197/
https://www.ncbi.nlm.nih.gov/pubmed/33145175
http://dx.doi.org/10.1016/j.eucr.2020.101467
work_keys_str_mv AT bilinskipretoria anexceptionalresponseto177lupsmaunderminedbyneuroendocrinetransformation
AT webbmyles anexceptionalresponseto177lupsmaunderminedbyneuroendocrinetransformation
AT bilinskipretoria exceptionalresponseto177lupsmaunderminedbyneuroendocrinetransformation
AT webbmyles exceptionalresponseto177lupsmaunderminedbyneuroendocrinetransformation

Ejemplares similares